Xellia Pharmaceuticals Overview

  • Year Founded
  • 1903

Year Founded

  • Status
  • Private

  • Employees
  • 1,800

Employees

  • Latest Deal Type
  • Debt

  • Financing Rounds
  • 4

  • Investments
  • 5

Xellia Pharmaceuticals General Information

Description

Developer of pharmaceutical ingredients designed for treatments against serious and life-threatening infections. The company's anti-infection treatments are genetically prepared that combat serious bacterial and antibiotic-resistant infections as well as certain fungal diseases, thereby helping clients with improved formulations, drug-device combinations, and in the long term, new anti-infection compounds.

Contact Information

Website
www.xellia.com
Formerly Known As
Axellia Pharmaceuticals, Apothekernes Laboratorium
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Corporate Office
  • Dalslandsgade 11
  • 2300 Copenhagen
  • Denmark
+45 32 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Xellia Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Xellia Pharmaceuticals‘s full profile, request access.

Request a free trial

Xellia Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pharmaceutical ingredients designed for treatments against serious and life-threatening infections. The com
Pharmaceuticals
Copenhagen, Denmark
1,800 As of 2023
00000
000000000 00000

000 00

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequa
000000000000000
Ballerup, Denmark
0000 As of 0000
00000
0.000 0000-00-00
0000000 0000 00000

000000

dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt u
0000 000000000
Jersey City, NJ
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xellia Pharmaceuticals Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
LEO Pharma Private Equity-Backed Ballerup, Denmark 0000 00000 0000000 0000 00000
Scynexis Formerly VC-backed Jersey City, NJ 00 00000 00000000 00000
Ability Pharma Venture Capital-Backed Barcelona, Spain 00 000.00 00000 00000
Kymab Formerly VC-backed Cambridge, United Kingdom 000 00000 000000&0 00000
Visterra Formerly VC-backed Waltham, MA 000 00000 000000&0 00000
You’re viewing 5 of 18 competitors. Get the full list »

Xellia Pharmaceuticals Patents

Xellia Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230255949-A1 Benzimidazole derivatives compositions Pending 11-Feb-2022 00000000000
CA-3204571-A1 Synthesis process Pending 11-Jan-2021 000000000
JP-2024502183-A Synthesis process Pending 11-Jan-2021 000000000
EP-4274842-A1 Synthesis process Pending 11-Jan-2021 000000000
AU-2021227095-A1 Daptomycin formulation Pending 28-Feb-2020 A61K9/19
To view Xellia Pharmaceuticals’s complete patent history, request access »

Xellia Pharmaceuticals Executive Team (13)

Name Title Board Seat Contact Info
Michael Kocher Chief Executive Officer
Craig Boyd President, US Injectables
Matthew Anderson Chief Financial Officer
Mikkel Olsen Chief Legal Officer & Corporate Development
John Stewart Chief Operations Officer
You’re viewing 5 of 13 executive team members. Get the full list »

Xellia Pharmaceuticals Board Members (9)

Name Representing Role Since
0000000 0000000 00 Self Board Member 000 0000
0000000 0000000 Self Board Member 000 0000
00000 0000 Self Board Member 000 0000
000000 00000 00000 Novo Holdings Board Member 000 0000
00000 000000 Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Xellia Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xellia Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Xellia Pharmaceuticals‘s full profile, request access.

Request a free trial

Xellia Pharmaceuticals Investments (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ben Venue Laboratories 25-Nov-2015 0000000000 Pharmaceuticals
Pharmaceuticals Manufacturing Facilities in Bedford 25-Nov-2015 0000000000 Buildings and Property 0000-0000
Xellia Manufacturing Facility (Grove, Illinois) 07-Jul-2014 0000000000 Buildings and Property 0000-0000
Phoenix Global Supply Group 13-May-2010 0000000000 Distributors (Healthcare) 0000-0000
Pharmaero 01-Jan-2009 Joint Venture Therapeutic Devices 000000000
To view Xellia Pharmaceuticals’s complete investments history, request access »

Xellia Pharmaceuticals Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
Xellia Manufacturing Facility (Grove, Illinois) 07-Jul-2014 0000000000 Completed
  • 2 buyers
To view Xellia Pharmaceuticals’s complete exits history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »